Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.38 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146031 | 0.86 | PIM1 (0.43) | PIM1KDM4EGAAMAPTKMT2A | |
| SCHEMBL31145988 | 0.79 | PIM1 (0.41) | PIM1KDM4EGAAMAPTKMT2A | |
| SCHEMBL31146039 | 0.74 | AGBL2 (0.36) | PIM1KDM4EGAAMAPTKMT2A | |
| SCHEMBL13271276 | 0.73 | KMT2A (0.58) | KDM4EMAPTKMT2AGRIN2DGRIN3B | |
| SCHEMBL31146266 | 0.72 | KDM4E (0.65) | PIM1KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL14485203 | 0.72 | KDM4E (0.65) | PIM1KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL31146222 | 0.70 | PIM1 (0.44) | PIM1KDM4EGAAMAPTKMT2A | |
| SCHEMBL31145855 | 0.70 | PIM1 (0.44) | PIM1KDM4EGAAMAPTKMT2A | |
| SCHEMBL31146143 | 0.70 | PIM1 (0.41) | PIM1KDM4EGAAMAPTKMT2A | |
| SCHEMBL31146223 | 0.70 | PIM1 (0.44) | PIM1KDM4EGAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206339-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | PIM1 3219/4885KDM4E 3988/4885GAA 258/4885 |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, COQ8A | PIM1 3219/4885KDM4E 3988/4885GAA 258/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | PIM1 4536/4885KDM4E 4379/4885GAA 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.